The companies will explore co-commercializing Labcorp's PGDx Elio Plasma Focus Dx liquid biopsy assay alongside Illumina's TruSight Oncology Comprehensive solid tumor test.
Shares of IlluminaILMN have risen 44.8% over the past year, reflecting strong momentum. The stock has outpaced the industry’s ...
A group of a few dozen colorful translucent 3D blobs, many of which overlap, contain brightly colored dots against a black background. Three-dimensional transcriptomics data from an instrument ...
Increased adoption of clinical whole-genome sequencing is advancing diagnostics for rare diseases, which affect 15 million American children SAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- Illumina, Inc.
SAN JOSE, Calif. and BASEL, Switzerland, Feb. 23, 2026 /PRNewswire/ -- Complete Genomics, a U.S.-based innovator in genomic sequencing technology, today confirmed that it has entered into a definitive ...
Twice the output, half the runtime, and half the footprint of the UG 100 ® with greater flexibility and improved genomic coverage Introducing two new high-throughput instrument configurations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results